Board of Directors
Peter R. Huntsman
Chairman of the Board, President and Chief Executive Officer
Peter R. Huntsman has served as an executive and Director of the Company and various affiliates since 1994. He presently serves as the Company’s President and Chief Executive Officer. Mr. Huntsman has served as Chairman of the Board of Directors since January 2018 and he sits on the Board’s Litigation Committee.
Prior to his appointment as Chief Executive Officer in July 2000, Mr. Huntsman served as the Company’s President and Chief Operating Officer, positions he held since 1994. He began his career at the Company working for Olympus Oil in 1983 and, in 1987, he joined Huntsman Polypropylene Corporation as Vice President before serving as its Senior Vice President and General Manager. Mr. Huntsman also served as Senior Vice President of Huntsman Chemical Corporation and as Senior Vice President of Huntsman Packaging Corporation, a former subsidiary. He currently serves as Non-executive Chairman and a director of Venator Materials PLC, a publicly-traded global pigments company headquartered in the U.K., which separated from the Company in 2017.
Mr. Huntsman has more than 30 years of experience in the global chemical industry and has held both operational and executive leadership positions in the United States and abroad. He has built extensive and lasting relationships with customers, suppliers, governmental and regulatory agencies, NGOs, labor unions, political leaders, and communities in which the Company operates around the world. He is widely recognized as a leader by and among his peers in the industry and recently became Vice Chairman of the Board of Directors of the American Chemistry Council, the industry’s trade, education and advocacy association representing more than $550 billion in enterprise value.
Charitable giving and civic engagement have been a hallmark of Huntsman Corporation since its founding 50 years ago and Mr. Huntsman is the Chairman and CEO of the Huntsman Cancer Foundation, which raises funds for and supports the ongoing research, treatment and educational programs of the world-renowned Huntsman Cancer Institute. He is also CEO of the Huntsman Foundation, which, most recently, committed $150 million to the University of Utah to establish the Huntsman Mental Health Institute, which is expected to become a nationally-recognized leader in mental health research, care, education and community outreach. Mr. Huntsman is a member of various executive boards and councils, including the Board of Overseers for the Wharton School of Business at the University of Pennsylvania; the Memorial Hermann Health Systems Board of Directors; the Executive Committee of The American Chemistry Council; the Board of Directors for the Cynthia Woods Mitchell Pavilion; and the Board of Advisors for Interfaith of The Woodlands. He also helps to direct a number of domestic and international humanitarian projects funded by the Huntsman family and Huntsman companies.
The Board has concluded that Mr. Huntsman, 57, should continue to serve as Chairman of the Board and Director because his current position as President and Chief Executive Officer enables him to bring invaluable operational, financial, regulatory and governance insights to the Board. His long and extensive role in the history and management of the Company and its affiliates enables him to continually educate and advise the Board on our business, the chemicals industry, and related opportunities and challenges. His broad and widely-recognized stature in the chemical industry globally ensures that the Company’s views and interests are represented on issues of importance to the Company and the chemical industry at every level.
Nolan D. Archibald
Vice Chairman of the Board, Chairman of the Nominating and Corporate Governance Committee and Lead Independent Director
Mr. Archibald has served as a Director since March 2005. He is currently Vice Chairman and Lead Director. Mr. Archibald is also Chairman of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Archibald served as Chairman and Chief Executive Officer of Black & Decker Corporation from 1987 to 2010. During that time, he led the transformation of Black & Decker into one of the most innovative and successful new product companies in the United States, driving significant growth via an innovation-driven new product pipeline and consistently ranking among the top recipient of patents granted by the US Patent and Trademark Office. He led the relaunch of the DeWalt brand in 1992 and built what is now the world’s largest professional power tools brand. He co-engineered the merger of Black & Decker with Stanley Works that significantly increased shareholder value. He served as Executive Chairman of the Board of the Stanley Black & Decker Corporation and chaired the Cost Synergy Committee that resulted in significant cost reduction and stock price appreciation.
Mr. Archibald has been cited by Business Week as one of the top six managers in the United States and Fortune Magazine as one of the country’s “Ten Most Wanted” executives. He also had extensive experience as a director of other large public companies, having served on the Boards of Lockheed Martin Corporation (where he served for 17 years including as Lead Director), ITT Corporation, and Brunswick Corporation. This experience enables him to contribute significantly to the Board’s oversight responsibilities.
The Board has concluded that Mr. Archibald, 76, should continue to serve as Vice Chairman and Lead Director of the Board because of his extensive executive‑level management experience and results with Black & Decker and Stanley Black & Decker. He brings to the Board significant CEO experience and a unique set of skills in product innovation, branding, marketing, and strategic planning, important areas for the Company as it continues to shift its portfolio further downstream into markets closer to the consumer and driven by innovation. Most recently, he has been providing significant leadership and guidance to the Company’s management team engaged in integrating the recently acquired Icynene-Lapolla spray foam polyurethane business and developing the go-forward branding strategies for Huntsman’s new leading business supplying spray foam products used to insulate commercial and residential structures.
As Lead Independent Director and Chairman of the Nominating and Corporate Governance Committee, Mr. Archibald is also leading the Board’s ongoing effort to add new Directors. Initiated just prior to the retirement of Jon Huntsman Sr., the Board refreshment process is fully underway and Mr. Archibald’s continued engagement with the professional search firm retained to assist the Company in identifying additional high-quality candidates and with the candidates themselves, will provide critical continuity and stability to the process.
M. Anthony Burns
Chairman of the Audit Committee and Director
Mr. Burns has been a Director of the Company since March of 2010. He presently serves as Chairman of the Audit Committee and sits on the Nominating and Corporate Governance Committee.
Since 2002, Mr. Burns has served as Chairman Emeritus of Ryder System, Inc., a provider of transportation and logistics services, and he held several executive level positions at Ryder before his retirement, including Chairman of the Board from 1985 to 2002, Chief Executive Officer from 1983 to 2000, and President and Chief Operating Officer from 1979 to 1999. While working at Ryder, Mr. Burns was a three-time recipient of Financial World magazine’s CEO of the Year Award and was also named its CEO of the Decade in its Transportation: Freight & Leasing sector. Prior to joining Ryder, he was a member of senior financial management at Mobil Oil Corporation. Mr. Burns has also had extensive experience on the boards of several U.S. publicly traded companies in a diverse range of industries. He served long tenures on the boards of Pfizer Inc.; J.P. Morgan Chase & Co.; Stanley Black & Decker; and J.C. Penney Company. On each of those public boards of directors, Mr. Burns served as chairman of the audit or compensation committees for most of his tenure.
Mr. Burns is a Life Trustee of the University of Miami in Florida and he has been active in charitable, cultural and civic organizations in Florida and nationally. He has served on the national boards of United Way of America, American Red Cross, National Urban League and Boy Scouts of America, as well as on the Foundation Board for the Malcolm Baldridge National Quality Award. Mr. Burns has also been the co-chairman of The Business Roundtable and chairman of its Health and Retirement Task Force. In his home state of Florida, he has served as chairman of the Capital Campaign for the Performing Arts Center of Greater Miami, board chairman and campaign chairman of the United Way of Miami-Dade County, and President of the Boy Scouts of America South Florida Council. In recognition of his extensive charitable work in the aftermath of Hurricane Andrew, Mr. Burns was named by the American Red Cross as its Humanitarian of the Year.
The Board has concluded that Mr. Burns, 77, should continue to serve as a director of the Company. His long tenure as Chairman and Chief Executive Officer of Ryder System, a major public company, and his extensive board experience at Pfizer and J.P. Morgan, among other public companies, enable him to provide the Board and executive management with steady leadership, strategic insight and valuable oversight into key strategic, financial and enterprise risk-related issues facing the Company in the ordinary course. In addition, his prior service on (and, in most cases, chairmanship of) audit committees for a diverse range of other public companies has provided him with invaluable financial expertise and significant experience with enterprise risk management and related systems, and enhances his ability to serve as chairman of the Company’s Audit Committee, where he functions as a principal steward of the financial health of the Company and quality of its investment grade balance sheet.
Wayne A. Reaud
Chairman of the Litigation Committee, Chairman of the Compensation Committee and Director
Mr. Reaud has served as a director of the Company since March 2005 and currently chairs both the Board’s Compensation Committee and its Litigation and Public Policy Committee. He is an accomplished trial lawyer and founder of the Beaumont, Texas law firm of Reaud, Morgan & Quinn. For more than 40 years, Mr. Reaud has represented clients in significant cases involving personal injury, product and premises liability, toxic torts and business litigation. He has handled first impression mass tort litigation involving asbestos premises liability claims, including the largest asbestos product liability class action lawsuit in the history of the Texas courts. He also represented the State of Texas in its landmark litigation against the tobacco industry, which resulted in the largest settlement of a single case in U.S. history at the time.
Among the many awards and recognition Mr. Reaud has received over the length of his career, he is a Life Fellow of the Texas Bar Foundation and a Fellow of the International Society of Barristers, a member of the Philosophical Society, and a member of the State Bar of Texas Grievance Committee. He was chosen as the Most Distinguished Alumni of Texas Tech University Law School in 1998 and also selected as the Most Distinguished Alumni of Lamar University in 2006. Mr. Reaud was awarded the Honorary Order of the Coif by the University of Texas School of Law in 2011. He is listed in Best Lawyers in America and has been named a “Super Lawyer” each year since 2006.
Mr. Reaud has also demonstrated an extraordinary commitment to public life and community service. He currently serves as Chairman of the Board of the Beaumont Foundation of America and is a Director of the Reaud Charitable Foundation. Since the Beaumont Foundation opened its doors in 2001, it has been devoted to aiding the poor and, to date, has provided more than $166 million to help those who face economic challenges in their lives. Through his work with the Reaud Charitable Foundation, Mr. Reaud established an endowed scholarship at the University of Texas School of Law to provide students dedicated to a career in public interest law with tuition and a stipend to support their work and educational development. Mr. Reaud serves on the Board of Directors of CBTX, Inc., a publicly-traded bank holding company for CommunityBank Texas N.A., an asset bank offering commercial banking solutions to local small and mid-sized businesses and professionals in Houston, Beaumont, Dallas and surrounding communities in Texas.
The Board has concluded that Mr. Reaud, 72, should continue to serve as a director because his significant legal expertise and extensive trial experience in complex, high‑profile cases enable him to advise the Board and executive management on material risks and successful risk mitigation strategies, and serve as a uniquely valuable resource for the Company’s legal department and its General Counsel. Going back to the Apollo/Hexion litigation, a series of “bet the company” cases litigated and ultimately settled in Huntsman’s favor, and continuing through today in material antitrust and other commercial litigation being pursued by or facing the Company, Mr. Reaud’s strategic insights and committed support have won and/or saved the Company hundreds of millions of dollars that have inured to the shareholders’ benefit. Mr. Reaud’s continued board service is further appropriate because of his demonstrated commitment to community service, education, public health, and cultural affairs mirrors the Company’s significant focus in these areas.
Dr. Mary C. Beckerle
Dr. Beckerle has served as a Director of the Company since May 2011 and sits on both the Audit Committee and the Nominating & Corporate Governance Committee. She is an internationally recognized scientist who has served on numerous national scientific boards and committees, including the Advisory Committee to the Director of the U.S. National Institutes of Health and the National Cancer Institute’s Board of Scientific Advisors. She is also a member of cancer policy and advisory boards at Harvard University, Georgetown University, University of Pennsylvania, and the National Center for Biological Sciences in Bangalore (India). Dr. Beckerle is a Distinguished Professor of Biology in the College of Science at the University of Utah, which she joined in 1986. She served as President of the American Society for Cell Biology in 2006, held a Guggenheim Fellowship at the Curie Institute in Paris, and is an elected Fellow of the American Academy of Arts and Sciences and the American Philosophical Society. Dr. Beckerle received the Utah Governor's Medal for Science and Technology in 2001, the Sword of Hope Award from the American Cancer Society in 2004, and, the Alfred G. Knudson Award in Cancer Genetics from the National Cancer Institute (NCI) in 2018.
Since 2006, Dr. Beckerle has served as Chief Executive Officer of Huntsman Cancer Institute at the University of Utah. In addition to her membership on the Board of Directors of the Company, Dr. Beckerle has, since 2015, been a member of the board of directors of Johnson & Johnson, a U.S. based multinational that manufactures and markets medical devices, pharmaceuticals and consumer-packaged goods around the world and one of the ten largest publicly traded companies in the U.S. At Johnson & Johnson, Dr. Beckerle chairs the company’s Science, Technology, and Sustainability Committee and serves as a member of the Board’s Regulatory Compliance Committee. She has been named as a National Association of Corporate Directors Directorship 100 awardee, which recognizes leading corporate directors and others who significantly impact boardroom practices and performance.
The Board has concluded that Dr. Beckerle, 65, should continue to serve as a Director owing to her executive management experience and her unique and extensive knowledge in the fields of cancer treatment, regulatory affairs and compliance. These skills bring added value to her service on the Company’s Audit Committee, which is responsible for enterprise risk assessment and mitigation oversight, and the Nomination & Corporate Governance Committee, which continues to exercise oversight responsibility for the Company’s EHS and product regulatory compliance functions, both critical areas of oversight for the chemical industry. Her long service as CEO of a National Cancer Institute-designated Comprehensive Cancer Center has provided her extensive skills and experience in both operational and strategic areas relevant to the Company’s operations, including a uniquely informed perspective on safety profiles of chemicals in our product portfolio and in our supply chain, product stewardship and regulatory compliance. Likewise, Dr. Beckerle’s tenure on the board of Johnson & Johnson, widely recognized as a leader in corporate governance best practice, brings a unique and valuable perspective to her service on the Company’s Board and its Nominating and Corporate Governance Committee. And, finally, her international academic and public policy experience allows her insight and valuable perspective into both challenges and opportunities related to the Company’s global business as well as to matters related to corporate governance, compliance and talent management, all of which are key areas of Board oversight responsibility.
Mr. Ferrari first joined the Company’s board of directors in March 2018, sits on the Compensation Committee, and previously served on the board’s Audit Committee. He is the Chief Executive Officer of Versalis S.p.A., one of Europe’s largest chemical companies with revenues in excess of $6 Billion and more than 7000 associates around the world. Mr. Ferrari also serves as Chairman of Matrìca S.p.A., a Versalis joint-venture with Novamont, an industry leader in bio-plastics. Matrìca sits at the vanguard of the renewable chemistry industry and operates an integrated “green” chemistry complex in Port Torres, Italy where they develop state-of-the-art products characterized by biodegradability and low toxicity and sourced from vegetable raw materials employing an integrated agricultural production chain. Matrìca represents sustainable solutions in the chemical industry, combining renewability and high performance.
Mr. Ferrari is a former senior executive at the Company and has more than 35 years of direct operating and executive experience in the chemical industry. He worked for Imperial Chemical Industries (ICI) and Agip Petroli, a subsidiary of Eni S.p.A., an international leading oil and gas company, before joining the Company in 1997, where he ultimately became President of the Performance Products division. Mr. Ferrari is presently serving as President of CEFIC, the European Chemical Industry Council, the largest trade association for the chemical industry in Europe, representing 29,000 chemical firms and interacting on their behalf with international and EU institutions, NGO’s, the international media, and other stakeholders, and he previously served as President of PlasticsEurope Bruxelles, an association of European plastics manufacturers. Mr. Ferrari is a Board Member of the recently-created Alliance to End Plastics Waste, a not-for-profit organization comprised of more than 40 global companies that have committed more than $1 billion (with the goal of investing $1.5 billion over the next 5 years) to help end plastic waste in the environment in partnership with the finance community, government and civil society, including environmental and economic development NGO’s. He is a member of the Board of Directors of Venator Materials PLC, which separated from Huntsman in 2017.
The Board has concluded that Mr. Ferrari, 59, should continue to serve as a Director because his more than 35 years of operating and executive experience in, and deep knowledge of, the global chemical industry, particularly in challenging European markets, enables him to provide valuable strategic insight into virtually every aspect of the Company’s business and properly exercise board oversight of its strategic business plans, the execution of its growth initiatives both organic and through M&A, its efforts to mitigate material process safety risk at its facilities and, finally, to ensure manufacturing asset integrity and reliability. Additionally, his executive leadership of the ongoing global repositioning and rebranding of Versalis, one of Europe’s largest chemical manufacturers, has provided him valuable insights and contacts within the sector, which supports the board’s stewardship of the Company’s own repositioning and branding downstream and its ongoing efforts to reload its business portfolio with higher margin, more specialty, differentiated, and renewable-based chemical products. Finally, Mr. Ferrari’s brings to the board significant leadership experience, knowledge and relationships in dealing with UN sustainable development goals, Circular Economy process, “eco-friendly” and renewables chemistry solutions owing to his service as Versalis CEO (through its BioTech global businesses), the Chairman of the Board of Matrìca S.p.A and his service on the board of the Alliance to End Plastic Waste.
Sir Robert J. Margetts
Sir Robert has been a Director of the Company since August 2010, and serves both on the Audit Committee, where he has been designated a financial expert, and on the Nominating & Corporate Governance Committee. He has more than 50 years of operating and executive experience in the chemical industry, going back to the beginning of his career with Imperial Chemical Industries PLC, a multinational chemical company based in United Kingdom where he ultimately rose to the role of Executive Vice Chairman. At ICI, Sir Robert led the global research, technology, engineering and manufacturing functions with responsibility for process safety and major hazard operations, among other things, and had executive leadership responsibility for many of ICI’s global business units. He was responsible for the divestment program associated with ICI’s transformation into a specialty chemical company, raising $10 billion in more than 30 separate transactions, including sales of ICI’s global polyurethanes, petrochemical and titanium dioxide businesses to Huntsman. His experience also included the start-up and development of a range of specialty chemical businesses and establishment and growth of ICI’s operations throughout Asia.
In addition to his long tenure in the chemical industry, Sir Robert has had substantial experience in the financial services and investment management sector. In 2000, he was elected Chairman of the Board of Legal & General PLC, a multinational financial services firm founded in 1836, where he oversaw a global business portfolio with more than £500 billion in assets under management. He has also served as Chairman of the BOC Group PLC, a publicly traded industrial gas business in the UK, which was ultimately sold to Linde AG for a substantial premium to shareholders. Since then, he has served as Senior Independent Director of two global mining companies, Anglo American PLC and PJSC Uralkali, and on the boards of directors of Wellstream PLC and Falk Renewables PLC. Sir Robert presently serves as Vice Chairman and Lead Independent Director of Venator Materials PLC, and he is Founder and Chairman of Ensus Ltd, a major bioethanol and protein producer and part of the CropEnergies Group, one of Europe’s leading manufacturers of sustainably produced bioethanol for the fuel sector today.
Sir Robert has also played an active role in the development and implementation of public policy in the United Kingdom over the course of his career, especially in the areas of climate change and sustainability. He served as Chairman of the Natural Environment Research Council, a non-departmental government agency in the UK responsible for national investment in the sciences relating to climate change and the environment. More recently, he established and chaired the Energy Technologies Institute, a public-private partnership charged with the development and demonstration of new low carbon energy technologies. Sir Robert’s many contributions to public life in science and engineering have been recognized with the awarding to him of the rank of Commander of the Most Excellent Order of the British Empire (CBE) and a Knighthood for services to business, the economy, and science and technology. He is also the recipient of many Honorary Fellowships, Doctorates and other awards, including membership in the Fellowship of the Royal Academy of Engineering (FREng), an honor given by the Royal Academy of Engineering to recognize the best and brightest engineers, inventors and technologists in the U.K. and around the world, promote excellence in engineering, and enhance and support engineering research, policy formation, education and entrepreneurship.
The Board has concluded that Sir Robert, 73, should continue to serve as a director owing to his extensive operating and executive experience in the global chemical industry, his broad executive and board leadership in a diverse range of other global industries, including financial services and investment management, and his strong background, acumen and experience in financial, business and operational matters arising in the ordinary course at the Company. Additionally, Sir Robert’s long and committed engagement in the public policy arena dealing with climate change and sustainability bring a critical perspective to the Board and executive management of the Company.
U.S. Navy Retired Vice Admiral Jan E. Tighe
U.S. Navy Retired Vice Admiral Tighe joined the Company’s Board of Directors in February 2019 and she currently serves as a member of the Board’s Audit Committee. In addition to her board service for the Company, she is a member of the boards of directors of The Goldman Sachs Group, a multinational investment bank and financial services company offering investment and asset management services, among others; Progressive Corporation, a property and casualty insurance company; and IronNet CyberSecurity, a global network security company serving the defense, financial services, energy and utilities, health care and life sciences industries. Vice Admiral Tighe also serves on the board of trustees for MITRE, as a board member for the U.S. Naval Academy Foundation, and as a strategic advisor to Paladin Capital Group, BluVector, RangeForce, and the Idaho National Laboratory National & Homeland Security Directorate. She has been a National Association of Corporate Directors Governance Fellow since 2018.
Before her retirement from the U.S. Navy in 2018, Vice Admiral Tighe served as the Deputy Chief of Naval Operations for Information Warfare where she had executive responsibilities as Director of Naval Intelligence, U.S. Navy's Chief Information Officer, Director of Cybersecurity, and as a member of the U.S. Navy’s Corporate Board, which collaboratively planned and financed $150 billion annually to support global U.S. Navy missions. She led planning and resource programming for Navy Information Warfare Capabilities, including Cyber Resiliency and IT Network Modernization, and spearheaded the Navy’s digital transformation, established a digital factory, and launched digital pilot projects that applied data science, artificial intelligence and machine learning to improve business productivity and mission operations.
Vice Admiral Tighe is a graduate of the U.S. Naval Academy and received her M.S. and Ph.D. degrees in Applied Mathematics and Electrical Engineering, respectively, from the U.S. Naval Postgraduate School (NPS). She later served as the President of NPS (from 2012 to 2013) and was inducted into the NPS Hall of Fame in June 2018 in recognition of her distinguished accomplishments and contributions at the highest levels of public service. During her 34-year Navy career, Vice Admiral Tighe served in various roles of increasing seniority for the Navy and National Security Agency including Commander of the U.S. Fleet Cyber Command, U.S. Tenth Fleet, where she directed operations and defense of Global Navy IT Networks, Signals Intelligence Operations and Offensive Cyberspace Operations.
The Board has concluded that Vice Admiral Tighe, 57, should continue to serve as a Director based on her diverse leadership experience and valuable global perspective she gained serving in the U.S. Navy and with the National Security Agency. She also provides the Board with unique knowledge and executive level expertise and oversight experience in the fields of cybersecurity and information technology, including architecting cyber resiliency into operational systems and directing complex cyber and intelligence operations, all of which are areas of increasing focus for the Company. Finally, she brings to the Board a broad experience in strategic planning, risk assessment and mitigation, and strategy execution across a variety of organizations.
Jon M. Huntsman
June 21, 1937 – February 2, 2018
Jon M. Huntsman was our founder and Chairman Emeritus of our company until his passing on February 2, 2018. Widely regarded as one of his generation's great industrialists, Mr. Huntsman leaves behind an extraordinary legacy. He was a pioneer in the chemical industry, having founded the Huntsman Container Company in 1970, which revolutionized packaging and plastics, and was the initial predecessor to what is today known as Huntsman Corporation. In 1974, Mr. Huntsman created the "clamshell" container for fast-food sandwiches and went on to invent as many as 30 other popular products, including the first plastic plates and bowls.
In 1982, Mr. Huntsman formed Huntsman Chemical Corporation in Salt Lake City. While serving as its Chairman and CEO, he led the Company through constant, rapid growth with myriad impeccably timed and well-integrated acquisitions. Today Huntsman Corporation and Venator Corporation (a public subsidiary of Huntsman Corporation) together represent an $11 billion global manufacturer and marketer of chemicals. In December 2017, the Board of Directors of Huntsman Corporation named Mr. Huntsman Director and Chairman Emeritus, and elected his son, Peter R. Huntsman, Chairman, President and CEO.
In his heart, Mr. Huntsman was first a philanthropist, and his life's ambition much greater than business. His mission was to find a cure for cancer and alleviate its ravaging effects on mankind. In 1995, he contributed $100 million to establish the Huntsman Cancer Institute, a pioneer in genetic research and treatment and today one of the world's most renowned cancer institutes and hospitals, located in Salt Lake City.